Park Gyuman, Yoon Byung Sun, Moon Jai-Hee, Kim Bona, Jun Eun Kyoung, Oh Sejong, Kim Hyunggee, Song Hea Joon, Noh Joo Young, Oh Chilhwan, You Seungkwon
Department of Dermatology, School of Medicine, Korea University, Seoul, Korea.
J Invest Dermatol. 2008 Oct;128(10):2429-41. doi: 10.1038/jid.2008.103. Epub 2008 May 8.
Keloids are benign skin tumors characterized by collagen accumulation and hyperproliferation of fibroblasts. To find an effective therapy for keloids, we explored the pharmacological potential of (-)-epigallocatechin-3-gallate (EGCG), a widely investigated tumor-preventive agent. When applied to normal and keloid fibroblasts (KFs) in vitro, proliferation and migration of KFs were more strongly suppressed by EGCG than normal fibroblast proliferation and migration (IC(50): 54.4 microM (keloid fibroblast (KF)) versus 63.0 microM (NF)). The level of Smad2/3, signal transducer and activator of transcription-3 (STAT3), and p38 phosphorylation is more enhanced in KFs, and EGCG inhibited phosphorylation of phosphatidylinositol-3-kinase (PI3K), extracellular signal-regulated protein kinase 1/2 (ERK1/2), and STAT3 (Tyr705 and Ser727). To evaluate the contribution of these pathways to keloid pathology, we treated KFs with specific inhibitors for PI3K, ERK1/2, or STAT3. Although a PI3K inhibitor significantly suppressed proliferation, PI3K and MEK/ERK inhibitors had a minor effect on migration and collagen production. However, a JAK2/STAT3 inhibitor and a STAT3 siRNA strongly suppressed proliferation, migration, and collagen production by KFs. We also found that treatment with EGCG suppressed growth and collagen production in the in vivo keloid model. This study demonstrates that EGCG suppresses the pathological characteristics of keloids through inhibition of the STAT3-signaling pathway. We propose that EGCG has potential in the treatment and prevention of keloids.
瘢痕疙瘩是一种良性皮肤肿瘤,其特征为胶原蛋白堆积和成纤维细胞过度增殖。为了找到治疗瘢痕疙瘩的有效方法,我们探索了(-)-表没食子儿茶素-3-没食子酸酯(EGCG)的药理潜力,EGCG是一种经过广泛研究的肿瘤预防剂。当在体外应用于正常和成纤维细胞(KFs)时,EGCG对KFs增殖和迁移的抑制作用比对正常成纤维细胞增殖和迁移的抑制作用更强(IC(50):54.4微摩尔/升(瘢痕疙瘩成纤维细胞(KF))对63.0微摩尔/升(正常成纤维细胞(NF)))。KFs中Smad2/3、信号转导及转录激活因子-3(STAT3)和p38磷酸化水平升高更明显,EGCG可抑制磷脂酰肌醇-3激酶(PI3K)、细胞外信号调节蛋白激酶1/2(ERK1/2)和STAT3(Tyr705和Ser727)的磷酸化。为了评估这些信号通路对瘢痕疙瘩病理的影响,我们用PI3K、ERK1/2或STAT3的特异性抑制剂处理KFs。虽然PI3K抑制剂显著抑制增殖,但PI3K和MEK/ERK抑制剂对迁移和胶原蛋白产生的影响较小。然而,JAK2/STAT3抑制剂和STAT3小干扰RNA强烈抑制KFs的增殖、迁移和胶原蛋白产生。我们还发现,在体内瘢痕疙瘩模型中,EGCG处理可抑制其生长和胶原蛋白产生。本研究表明,EGCG通过抑制STAT3信号通路抑制瘢痕疙瘩的病理特征。我们认为EGCG在瘢痕疙瘩的治疗和预防方面具有潜力。